Last checked at 9 Apr 2020 07:30
9 April 2020
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Further re Subscription and Issue of Equity in lieu of fees
Further to the announcement made earlier today, Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that several directors have subscribed for, in aggregate, 760,000 Subscription Shares at the Issue Price as part of the Subscription.
Details of the participation by certain directors in the Subscription is set out below.
In addition, a number of the Directors have agreed to receive shares in lieu of salaries, fees and bonuses owed, details of which are set out below. This will result in the issue of 825,944 new ordinary shares ("New Ordinary Shares") at the Issue Price.
Director | Number of Subscription Shares | Number of New Ordinary Shares |
Michael Sinclair (Executive Chairman) | 400,000 | 265,944 |
Enrico Vanni (Non-Executive Director) | 300,000 | 120,000 |
Gabriel Urwitz (Non-Executive Director) | 60,000 | - |
Stephen Myers (Executive Director) | - | 200,000 |
Nick Plowman (Non-Executive Director) | - | 120,000 |
Hans Von Celsing (Non-Executive Director) | - | 120,000 |
Further, a number of senior management have agreed to receive shares in lieu of bonuses owed. This will result in the additional issue of 65,542 New Ordinary Shares at the Issue Price.
The definitions that apply throughout this announcement are as set out in the announcement made earlier today.
Admission and Total Voting Rights
Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on or around 15 May 2020 ("Admission").
Upon Admission, the Company's enlarged issued share capital will comprise 305,644,992 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights will be 305,644,992.
The aforementioned figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.
- ENDS -
Advanced Oncotherapy plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO | |
Allenby Capital Limited (Nomad & Broker) | |
Nick Athanas / Liz Kirchner / Nicholas Chambers | Tel: +44 (0) 20 3328 5656 |
FTI Consulting (Financial PR & IR) | advancedoncotherapy@fticonsulting.com |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities | |||||||
a) | Name | PDMRs:
| ||||||
2 | Reason for the notification | |||||||
a) | Position/status | See 1a) above | ||||||
b)
| Initial notification /Amendment | Initial notification | ||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Advanced Oncotherapy plc | ||||||
b) | LEI | 213800LUDHZOG3YT6C82 | ||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of 25p each in Advanced Oncotherapy plc Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109 | ||||||
b) | Nature of the transaction | Participation in a fundraise
| ||||||
c) | Price(s) and volume(s) | Price: 25p
Volumes:
| ||||||
d) | Aggregated information - Aggregated volume - Price | n/a | ||||||
e) | Date of the transaction | 9 April 2020
| ||||||
f) | Place of the transaction | Outside a Trading Venue | ||||||
1 | Details of the person discharging managerial responsibilities | |||||||||||||
a) | Name | PDMRs:
| ||||||||||||
2 | Reason for the notification | |||||||||||||
a) | Position/status | See 1a) above | ||||||||||||
b)
| Initial notification /Amendment | Initial notification | ||||||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | Advanced Oncotherapy plc | ||||||||||||
b) | LEI | 213800LUDHZOG3YT6C82 | ||||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of 25p each in Advanced Oncotherapy plc Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109 | ||||||||||||
b) | Nature of the transaction | Issue of ordinary shares in consideration of payment of fees/bonuses
| ||||||||||||
c) | Price(s) and volume(s) | Price: 25p
Volumes:
| ||||||||||||
d) | Aggregated information - Aggregated volume - Price | n/a | ||||||||||||
e) | Date of the transaction | 9 April 2020
| ||||||||||||
f) | Place of the transaction | Outside a Trading Venue | ||||||||||||